Summary
Amgen Inc. (AMGN) filed an 8-K on April 11, 2007, reporting a significant change in its executive leadership. Richard D. Nanula has resigned as Executive Vice President and Chief Financial Officer, effective April 10, 2007. Mr. Nanula will remain with the company for 90 days to facilitate a smooth transition. This departure marks the end of Mr. Nanula's tenure in a key financial role for the biopharmaceutical giant. Concurrently, Amgen has appointed Robert A. Bradway as the new Executive Vice President and Chief Financial Officer, also effective April 10, 2007. Mr. Bradway brings substantial financial and healthcare industry experience, having spent 18 years at Morgan Stanley, where he held senior leadership positions in investment banking, including leading the European healthcare practice. His appointment signals a new phase for Amgen's financial management, leveraging his extensive background.
Key Highlights
- 1Resignation of Richard D. Nanula as EVP and CFO, effective April 10, 2007.
- 2Richard D. Nanula will provide transition assistance for 90 days.
- 3Appointment of Robert A. Bradway as the new EVP and CFO, effective April 10, 2007.
- 4Robert A. Bradway has extensive experience from an 18-year career at Morgan Stanley.
- 5Mr. Bradway previously served as VP, Operations Strategy at Amgen since joining in 2006.
- 6Mr. Bradway's compensation includes a $750,000 base salary and a bonus target of 70% of base.
- 7Mr. Bradway will receive a grant of 60,000 stock options.